Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. BRAIN Biotech AG
  6. News
  7. Summary
    BNN   DE0005203947


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

PRESS RELEASE : BRAIN Biotech AG: Sartorius and BRAIN jointly researching and adapting novel CRISPR Cas-nucleases

07/28/2021 | 02:31am EDT
DGAP-News: BRAIN Biotech AG / Key word(s): Miscellaneous 
BRAIN Biotech AG: Sartorius and BRAIN jointly researching and adapting novel CRISPR Cas-nucleases 
2021-07-28 / 08:30 
The issuer is solely responsible for the content of this announcement. 
Goettingen / Zwingenberg (Germany), July 28, 2021 
Sartorius and BRAIN jointly researching and adapting novel CRISPR Cas-nucleases 
The life science group Sartorius and BRAIN Biotech AG are jointly researching and adapting novel CRISPR-Cas genome 
editing nucleases for specific applications in the field of life sciences. Genome editing enables the targeted and 
precise insertion, deletion, or modification in the genome of a living organism. Within the research project Sartorius 
is testing the novel CRISPR-Cas genome editing nucleases on a range of cell lines. "In this way, we target to increase 
the performance of our cell lines in various directions to accelerate the entire development and manufacturing process 
of future biopharmaceuticals and make it more cost-effective," Dr. Oscar-Werner Reif, Head of Corporate Research and 
Chief Technology Officer at Sartorius comments. 
To this end, Sartorius and BRAIN are collaborating on a promising early-stage genome editing technology portfolio. Reif 
states: "Sartorius and BRAIN share the vision that the future genome editing market will strongly benefit from a 
further diversification and differentiation of Cas-nucleases. Our joined intention is to advance the technology in our 
dedicated application field from research level to a successful commercialization." 
Dr. Michael Krohn, Head R&D at BRAIN Biotech AG says: "We are very pleased to cooperate from a very early stage on with 
Sartorius AG for an application of our novel BRAIN Engineered CAS (BEC) genome editing nucleases in the field of life 
sciences. Sartorius has very valuable application know-how to utilize our BEC tool in this specific area. With our 
cooperation, we can speed up the development and create a valuable joint IP portfolio". 
Novel CRISPR-Cas genome editing nucleases can be used to modify the genetic material of cells by specifically altering 
genes, inserting them into the genome or removing them from it. Scientists can use this biotechnological gene editing 
process, for example, to make plants more resistant to pests and drought or to produce biological fuels. In 
biopharmaceuticals, the gene scissors could lead to new therapies and thus improve the chances of curing a wide range 
of diseases such as cancer, neurodegenerative diseases or hereditary diseases. 
A profile of Sartorius 
The Sartorius Group is a leading international partner of life science research and the biopharmaceutical industry. 
With innovative laboratory instruments and consumables, the Group's Lab Products & Services Division concentrates on 
serving the needs of laboratories performing research and quality control at pharma and biopharma companies and those 
of academic research institutes. The Bioprocess SolutionsDivision with its broad product portfolio focusing on 
single-use solutions helps customers to manufacture biotech medications and vaccines safely and efficiently. The Group 
has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of 
complementary technologies. In fiscal 2020, the company earned sales revenue of some 2.34 billion euros. At the end of 
2020, nearly 11,000 people were employed at the Group's approximately 60 manufacturing and sales sites, serving 
customers around the globe. 
About BRAIN 
BRAIN Biotech AG ("BRAIN") is a leading European specialist in industrial biotechnology. As a technology provider and 
developer of bio-based products and solutions for nutrition, health and the environment, the company supports the 
biologization of industry and contributes to a more sustainable economy. BRAIN is the parent company of the BRAIN 
Group. Two pillars form BRAIN Group's business: The BioScience segment includes contract research for renowned 
industrial partners as well as an incubator for the development of the company's own highly innovative products. In the 
BioIndustrial segment, the company focuses on specialty business in the production and refinement of enzymes, 
microorganisms and bioactive natural products and the respective distribution. 
The BRAIN Group maintains its own diverse collection of natural resources: the BRAIN Bioarchive comprises 
microorganisms, genetic material and natural substances. Based on this collection and with a comprehensive technology 
portfolio, BRAIN addresses technological challenges and develops bio-based products and solutions that are already 
successfully employed in the industry. The BRAIN Group has its own production facilities in Germany, UK and the US, 
which together with the associated biotechnological production expertise, complete the value chain within the Group. 
As a Participant of the United Nations Global Compact, BRAIN Biotech AG is committed to aligning strategies and 
operations with universal principles on human rights, labour, environment and anti-corruption, and take actions that 
advance societal goals. 
Since its IPO in 2016, BRAIN Biotech AG has been listed in the Prime Standard of the Frankfurt Stock Exchange (ISIN 
DE0005203947 / WKN 520394). 
This press release contains forward-looking statements. These statements reflect the current views, expectations, and 
assumptions of the management of BRAIN Biotech AG, and are based on information currently available to the management. 
Forward-looking statements are no guarantees of future performance, and entail both known and unknown risks as well as 
uncertainties that could cause actual results, performance or events to differ materially from those expressed or 
implied in such statements. Numerous factors exist that could influence the future performance by, and future 
developments at, BRAIN Biotech AG and the BRAIN Group. Such factors include, but are not limited to, changes in the 
general economic and competitive environment, risks associated with capital markets, currency exchange rate 
fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and 
regulations, as well as other factors. 
BRAIN Biotech AG does not undertake any obligation to update or revise any forward-looking statements. 
Contact Investor Relations 
Michael Schneiders 
Head of Investor Relations & Sustainability 
Phone: +49 6251 9331-86 
Email: mis@brain-biotech.com 
Media Contact 
Dr. Stephanie Konle 
PR & Corporate Communications 
Phone: +49 6251 9331-70 
Email: stk@brain-biotech.com 
Follow BRAIN Biotech on Twitter (@BRAINbiotech) and on LinkedIn (@BRAIN AG) 
2021-07-28 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. 
The issuer is solely responsible for the content of this announcement. 
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. 
Archive at www.dgap.de 
Language:     English 
Company:      BRAIN Biotech AG 
              Darmstädter Straße 34-36 
              64673 Zwingenberg 
Phone:        +49 (0) 62 51 / 9331-0 
Fax:          +49 (0) 62 51 / 9331-11 
E-mail:       ir@brain-biotech.com 
Internet:     www.brain-biotech.com 
ISIN:         DE0005203947 
WKN:          520394 
Listed:       Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, 
              Hamburg, Munich, Stuttgart, Tradegate Exchange 
EQS News ID:  1222105 
End of News   DGAP News Service 

1222105 2021-07-28

Image link: 

(END) Dow Jones Newswires

July 28, 2021 02:30 ET (06:30 GMT)

Stocks mentioned in the article
ChangeLast1st jan.
BRAIN BIOTECH AG 0.40% 10 Delayed Quote.10.18%
SARTORIUS STEDIM BIOTECH -5.77% 487.7 Real-time Quote.77.82%
All news about BRAIN BIOTECH AG
09/16BRAIN BIOTECH AG : Release according to Article 41 of the WpHG [the German Securities Trad..
09/15BRAIN BIOTECH : successfully placed new share capital for the financing of further growth ..
09/15BRAIN BIOTECH AG : BRAIN Biotech AG has successfully completed 10% cash capital increase f..
09/15BRAIN BIOTECH : successfully placed new share capital for the financing of further growth ..
09/15PRESS RELEASE : BRAIN Biotech AG successfully placed new share capital for the financing o..
09/15BRAIN BIOTECH AG : BRAIN Biotech AG -2-
09/15BRAIN BIOTECH AG : BRAIN Biotech AG has successfully completed 10% cash capital increase f..
09/15BRAIN BIOTECH : resolves on a cash capital increase from authorised capital
09/15BRAIN BIOTECH : resolves on a 10% cash capital increase from authorised capital with exclu..
09/15BRAIN BIOTECH : resolves on a cash capital increase from authorised capital
More news
Analyst Recommendations on BRAIN BIOTECH AG
More recommendations
Sales 2021 39,3 M 46,0 M 46,0 M
Net income 2021 -7,18 M -8,40 M -8,40 M
Net Debt 2021 9,32 M 10,9 M 10,9 M
P/E ratio 2021 -28,6x
Yield 2021 -
Capitalization 218 M 255 M 255 M
EV / Sales 2021 5,78x
EV / Sales 2022 5,14x
Nbr of Employees 297
Free-Float 52,5%
Duration : Period :
BRAIN Biotech AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BRAIN BIOTECH AG
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 5
Last Close Price 9,96 €
Average target price 15,66 €
Spread / Average Target 57,2%
EPS Revisions
Managers and Directors
Adriaan Moelker Chief Executive Officer
Lukas Linnig Chief Financial Officer
Georg Kellinghusen Chairman-Supervisory Board
Michael Krohn Executive VP & Head-Research & Development
Anna Carina Eichhorn Deputy Chairman-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
SUEZ21.42%14 740